



**BioLight Life Sciences Ltd.**

(the "Company")

January 29, 2025

**To: Israel Security Authority**  
**[www.isa.gov.il](http://www.isa.gov.il)**

**TASE Tel Aviv Stock Exchange**  
**[www.tase.co.il](http://www.tase.co.il)**

**Re: Update Regarding License Option and Animal Trial Results at OphRx (Subsidiary Company)**

Following the Company's report from February 29, 2024[1] regarding signing an agreement with a global pharmaceutical company ("**Pharma Company**") for research collaboration and granting an exclusive license option for one of OphRx's developments (a subsidiary of the Company[2]) (the "**Agreement**"), the Company hereby announces that OphRx, which develops an innovative technology platform based on nanostructures for eye drug delivery via drops to target tissue ("**OphRx Technology**"), has informed that the joint animal trial conducted under the Agreement to examine delivery of a specific active ingredient to the retina via eye drops based on OphRx Technology and examining its clinical activity in an accepted animal model for AMD (Age-related Macular Degeneration)[3] treatment, yielded positive results.

According to trial results, treatment administered to pigs using drops based on OphRx Technology with the tested active ingredient yielded similar results to those achieved through injection of one of the most commonly used drugs today for AMD treatment. Both treatments were given within the same study as different research groups. Additionally, the amount of active ingredient measured in the retina via drops was significantly higher than the accepted threshold value in literature required to achieve biological effect.

As reported to the Company, on January 28 2025 the Pharma Company informed OphRx they decided not to exercise the option granted to them under the Agreement and to pursue with technology developed by them.

As reported to the Company, OphRx intends to pursue commercialization of OphRx Technology and development of the specific product tested in the trial, subject to required regulation in each territory, through collaboration with other companies and entities. It should be noted there is no certainty that OphRx's actions as stated will materialize into binding agreements.

***Forward-Looking Statement** - The information, details and Company assessments included in this report regarding trial results and the possibility of developing OphRx's product, its manufacturing and commercialization and creating collaborations for this purpose, constitute "forward-looking information" as defined in the Securities Law, 1968, involving high uncertainty, and based, among others, on third parties and many variables over which the Company and OphRx do not necessarily have control, and therefore the information, details and assessments may not materialize and/or not fully materialize and/or materialize substantially differently than initially assessed or anticipated.*

## **About the Company**

The Company holds and invests in companies ("Portfolio Companies") in the field of eye diseases and treatments through investment, management, development, and commercialization of projects and technologies and/or products in the fields of advanced medical devices, drugs, diagnostics, and digital medicine in the eye field (together - "Eye Products"), which aim to address real needs in the field of eye diseases and treatments. The Portfolio Companies and their various Eye Products are at different developmental, clinical (or pre-clinical), and commercial stages, ranging from initial development to sales.

Sincerely,

BioLight Life Sciences Ltd.

[1] Reference number: 2024-01-020919, incorporated by reference ("Original Report").

[2] The Company holds approximately 57% of OphRx's issued and outstanding share capital (57% fully diluted).

[3] For additional details regarding the animal trial and Agreement with the Pharma Company, see the Original Report.